What is retatrutide?
Retatrutide is an investigational once-weekly injection made by Eli Lilly, the company behind tirzepatide. It is a single molecule built to activate three hormone receptors at once: GLP-1, GIP and glucagon. That is why it is often called a “triple agonist.”
Its status is simple to state. As of October 2026, retatrutide is not approved by the FDA for any use. In its July 23, 2026 announcement, Lilly said it is completing the manufacturing data package and plans to submit retatrutide for U.S. approval in the first quarter of 2027. The same release states that retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.
Lilly is studying it well beyond weight. Its trials cover obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, heart and kidney outcomes, and fatty liver disease. The first filing is expected to focus on obesity, knee osteoarthritis pain and sleep apnea.
How does acting on three receptors work?
Each receptor adds a different lever. GLP-1 activation slows stomach emptying and reduces appetite, the same core action as semaglutide. GIP activation adds to the appetite and blood-sugar effects, as it does with tirzepatide. Glucagon activation is the new piece: glucagon normally tells the liver to release stored energy, and researchers think adding it may raise energy use and help clear liver fat.
| Medicine | GLP-1 | GIP | Glucagon | FDA status, October 2026 |
|---|---|---|---|---|
| Semaglutide | Yes | No | No | Approved |
| Tirzepatide | Yes | Yes | No | Approved |
| Retatrutide | Yes | Yes | Yes | Investigational |
The glucagon piece is also a reason for careful study. In the phase 2 trial, heart rate rose with dose, peaking around week 24 before easing, which is one of the signals larger trials are designed to track.
What have the trials shown?
The results so far are large. In the phase 2 trial published in the New England Journal of Medicine, adults with obesity on the 12 mg dose lost an average of 24.2 percent of body weight at 48 weeks, and weight had not yet leveled off when the study ended.
Phase 3 data, from the TRIUMPH program, followed in 2026. In Lilly’s July release:
- TRIUMPH-2 (obesity or overweight with type 2 diabetes, 1,152 adults): average loss of 12.7, 19.1 and 20.8 percent at 4, 9 and 12 mg over 80 weeks, versus 4.0 percent on placebo, with A1C falling by up to 1.6 points.
- TRIUMPH-3 (severe obesity with established heart disease, 1,949 adults): average loss of 21.6 and 22.6 percent at 9 and 12 mg over 80 weeks, versus 3.2 percent on placebo.
Two cautions belong next to those numbers. These are company-reported topline results that have not yet been through full peer review, and the trial registry for TRIUMPH-1 and its sister studies is where final results will be posted. Also, the reported figures use an “efficacy estimand,” which assumes everyone stayed on the drug.
What are the side effects so far?
The side-effect profile looks like a stronger version of the GLP-1 class. In TRIUMPH-2, the most common problems were diarrhea, nausea, constipation, reduced appetite and vomiting, all more frequent at higher doses. Lilly also reported dysesthesia, an altered or uncomfortable skin sensation, more often than with placebo.
Stopping because of side effects was not rare. In TRIUMPH-3, 9.8 percent of people on 9 mg and 13.5 percent on 12 mg quit for adverse events, compared with 4.8 percent on placebo. A full safety picture, including the heart-rate signal and long-term effects, will come from the FDA’s review of the complete data.
Why gray-market “research” retatrutide is not legal medicine
Vials of retatrutide are widely advertised online as research chemicals, often with dosing charts that make clear they are meant for people. The FDA’s page on unapproved GLP-1 drugs says retatrutide cannot be used in compounding under federal law, and that it has warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide. It also warns that products labeled “for research purposes” or “not for human consumption” are of unknown quality.
What that means in practice:
- No legal source. The maker does not sell it, and pharmacies cannot compound it.
- Unknown contents. Unapproved GLP-1 products may hold too much, too little or none of the active drug, or the wrong ingredient.
- Contamination risk. Powders made outside drug-quality manufacturing can carry impurities or bacterial toxins, and sterility is not verified.
- No safety net. Without monitoring labs or a clinician managing the dose, problems such as dehydration, pancreatitis or a racing heart may be missed.
If you have injected a research product and develop severe belly pain, fainting, a racing or irregular heartbeat, or trouble breathing, call 911 or go to the ER. Our answer on whether research peptides are safe covers the wider gray market.
What Ultimate Male uses in the meantime
Ultimate Male does not offer retatrutide, and will not source it while it remains unapproved. The clinic’s medical weight loss program uses FDA-approved GLP-1 medicines: semaglutide and tirzepatide, which already produce substantial weight loss for many men. Your PA-C or MD picks between them after an evaluation, labs and body composition analysis, and our semaglutide versus tirzepatide comparison for men explains how that choice usually goes.
Weight loss that lasts also depends on protecting muscle while you lose. The body composition analysis at the start and at follow-ups shows whether you are losing fat or lean tissue.
If retatrutide is approved, your provider can talk through whether it fits your situation at that time. Until then, start with a free 10-minute phone call at 626-319-5261.
